{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:41:01Z","timestamp":1791578461611,"version":"4.3.4"},"reference-count":127,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The emergence and spread of\n                      <jats:italic toggle=\"yes\">Trichophyton indotineae<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">T. indotineae<\/jats:italic>\n                      ) has led to a sea change in the prescription practices of clinicians regarding the management of dermatophytic skin infections. An infection easily managed with a few weeks of antifungals, tinea corporis or cruris, is now often chronic and recurrent and requires prolonged treatment. Rising resistance to terbinafine, with documented squalene epoxidase (SQLE) gene mutations, and slow clinical response to itraconazole leave clinicians with limited treatment choices. However, in these testing times, it is essential that the tenets of antifungal stewardship be followed in making therapeutic decisions, and that the existing armamentarium of antifungals be used in rationale ways to counter this extremely common cutaneous infection, while keeping the growing drug resistance among dermatophytes in check. This review provides updated evidence on the use of various systemic antifungals for dermatophytic infection of the glabrous skin, especially with respect to the emerging\n                      <jats:italic toggle=\"yes\">T. indotineae<\/jats:italic>\n                      species, which is gradually becoming a worldwide concern.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_832_23","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:15:36Z","timestamp":1724951736000},"page":"525-540","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic Updates on the Management of Tinea Corporis or Cruris in the Era of Trichophyton Indotineae"],"prefix":"10.4103","volume":"68","author":[{"given":"Ananta","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Sharath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Sardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet","family":"Panesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240829","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.fgb.2019.103255","article-title":"Antifungal resistance in dermatophytes: Recent trends and therapeutic implications","volume":"132","author":"Khurana","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"R2-8-20240829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mmcr.2022.05.004","article-title":"First detection of Trichophyton indotineae causing tinea corporis in central Vietnam","volume":"36","author":"Ngo","year":"2022","journal-title":"Med Mycol Case Rep"},{"key":"R3-8-20240829","doi-asserted-by":"crossref","first-page":"1113065","DOI":"10.3389\/fimmu.2022.1113065","article-title":"The epidemic of the multiresistant dermatophyte Trichophyton indotineae has reached China","volume":"13","author":"Jia","year":"2023","journal-title":"Front Immunol"},{"key":"R4-8-20240829","first-page":"460","article-title":"Trichophyton mentagrophytes\u2014A new genotype in Cambodia","volume":"5","author":"Uhrlass","year":"2019","journal-title":"J Fungi"},{"key":"R5-8-20240829","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/jof8020150","article-title":"Increasing terbinafine resistance in Danish Trichophyton isolates 2019\u20132020","volume":"8","author":"Astvad","year":"2022","journal-title":"J Fungi (Basel"},{"key":"R6-8-20240829","first-page":"1723","article-title":"\u201cIndian\u201d strains of Trichophyton mentagrophytes with reduced itraconazole susceptibility in Germany","volume":"19","author":"Brasch","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"R7-8-20240829","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3201\/eid2801.210883","article-title":"Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, France","volume":"28","author":"Jabet","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"R8-8-20240829","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/jof7060419","article-title":"Molecular epidemiology and antifungal susceptibility of trichophyton isolates in Greece: Emergence of terbinafine-resistant trichophytonmentagrophytes type VIII locally and globally","volume":"7","author":"Siopi","year":"2021","journal-title":"J Fungi (Basel"},{"key":"R9-8-20240829","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/12034754221077891","article-title":"Terbinafine resistant Trichophyton indotineae isolated in patients with superficial dermatophyte infection in Canadian patients","volume":"26","author":"Posso-De","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"R10-8-20240829","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/IDR.S246025","article-title":"Emergence of terbinafine resistant Trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene","volume":"13","author":"Taghipour","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R11-8-20240829","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/jdv.17106","article-title":"Epidemiological and clinical aspects of Trichophyton mentagrophytes\/Trichophyton interdigitale infections in the Zurich area: A retrospective study using genotyping","volume":"35","author":"Klinger","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-8-20240829","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/jdv.17241","article-title":"Emerging antifungal treatment failure of dermatophytosis in Europe: Take care or it may become endemic","volume":"35","author":"Saunte","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-8-20240829","doi-asserted-by":"crossref","first-page":"103266","DOI":"10.1016\/j.fgb.2019.103266","article-title":"A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes\/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile","volume":"133","author":"Singh","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"R14-8-20240829","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/myc.12772","article-title":"High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene","volume":"61","author":"Singh","year":"2018","journal-title":"Mycoses"},{"key":"R15-8-20240829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/myc.12865","article-title":"Perspectives on misidentification of Trichophyton interdigitale\/Trichophyton mentagrophytes using internal transcribed spacer region sequencing: Urgent need to update the sequence database","volume":"62","author":"Chowdhary","year":"2019","journal-title":"Mycoses"},{"key":"R16-8-20240829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/myc.12848","article-title":"A clarion call for preventing taxonomical errors of dermatophytes using the example of the novel Trichophyton mentagrophytes genotype VIII uniformly isolated in the Indian epidemic of superficial dermatophytosis","volume":"62","author":"Nenoff","year":"2019","journal-title":"Mycoses"},{"key":"R17-8-20240829","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11046-020-00455-8","article-title":"Trichophyton indotineae sp. nov.: A New Highly Terbinafine-Resistant Anthropophilic Dermatophyte Species","volume":"185","author":"Kano","year":"2020","journal-title":"Mycopathologia"},{"key":"R18-8-20240829","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11046-021-00544-2","article-title":"Taxonomy of the Trichophyton mentagrophytes\/T. interdigitale Species Complex Harboring the Highly Virulent, Multiresistant Genotype T. indotineae","volume":"186","author":"Tang","year":"2021","journal-title":"Mycopathologia"},{"key":"R19-8-20240829","doi-asserted-by":"crossref","first-page":"e02522","DOI":"10.1128\/AAC.02522-17","article-title":"Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance","volume":"62","author":"Rudramurthy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-8-20240829","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/myc.13091","article-title":"Alarming India-wide phenomenon of antifungal resistance in dermatophytes: A multicentre study","volume":"63","author":"Ebert","year":"2020","journal-title":"Mycoses"},{"key":"R21-8-20240829","doi-asserted-by":"crossref","first-page":"e1010795","DOI":"10.1371\/journal.ppat.1010795","article-title":"The emergence and worldwide spread of the species Trichophyton indotineae causing difficult-to-treat dermatophytosis: A new challenge in the management of dermatophytosis","volume":"18","author":"Chowdhary","year":"2022","journal-title":"PLoS Pathog"},{"key":"R22-8-20240829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/bst0180045","article-title":"Inhibition of squalene epoxidase and steroi side-chain methylation by allylamines","volume":"18","author":"Ryder","year":"1990","journal-title":"Biochem Soc Trans"},{"key":"R23-8-20240829","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1128\/AAC.47.11.3634-3636.2003","article-title":"In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine","volume":"47","author":"Osborne","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-8-20240829","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/AAC.01600-05","article-title":"Biological, biochemical, and molecular characterization of new clinical Trichophyton rubrum isolate resistant to terbinafine","volume":"50","author":"Osborne","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-8-20240829","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.47.1.82-86.2003","article-title":"Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine","volume":"47","author":"Mukherjee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-8-20240829","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1989.tb00908.x","article-title":"Clinical efficacy and tolerability of terbinafine (Lamisil)-a new topical and systemic fungicidal drug for treatment of dermatomycoses","volume":"14","author":"Villars","year":"1989","journal-title":"Clin Exp Dermatology"},{"key":"R28-8-20240829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199243020-00010","article-title":"Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses","volume":"43","author":"Balfour","year":"1992","journal-title":"Drugs"},{"key":"R29-8-20240829","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.1989.01670230079013","article-title":"A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis","volume":"125","author":"Cole","year":"1989","journal-title":"Arch Dermatol"},{"key":"R30-8-20240829","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2133.1994.tb04983.x","article-title":"One-week therapy with oral terbinafine in cases of tinea cruris\/corporis","volume":"131","author":"Farag","year":"1994","journal-title":"Br J Dermatol"},{"key":"R31-8-20240829","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/0019-5154.190120","article-title":"Relapse after oral terbinafine therapy in dermatophytosis: A clinical and mycological study","volume":"61","author":"Majid","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R32-8-20240829","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4103\/ijd.IJD_191_17","article-title":"Efficacy and safety of terbinafine 500 mg once daily in patients with dermatophytosis","volume":"62","author":"Babu","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R33-8-20240829","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/ijd.IJD_435_17","article-title":"Rational for drug dosimetry and duration of terbinafine in the context of recalcitrant dermatophytosis: Is 500 mg better than 250 mg OD or BD?","volume":"62","author":"Sardana","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R34-8-20240829","doi-asserted-by":"crossref","first-page":"e01038","DOI":"10.1128\/AAC.01038-18","article-title":"Correlation of In vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis\/cruris","volume":"62","author":"Khurana","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-8-20240829","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R36-8-20240829","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.02661-13","article-title":"Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum","volume":"58","author":"Elefanti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-8-20240829","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards","volume":"24","author":"Rex","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R38-8-20240829","doi-asserted-by":"crossref","first-page":"e01964","DOI":"10.1128\/AAC.01964-19","article-title":"MIC and upper limit of wild-type distribution for 13 antifungal agents against a trichophyton mentagrophytes-trichophyton interdigitale complex of Indian origin","volume":"64","author":"Shaw","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-8-20240829","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.49.7.2840-2844.2005","article-title":"Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine","volume":"49","author":"Osborne","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-8-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2340\/00015555-2455","article-title":"Darier disease complicated by terbinafine-resistant Trichophyton rubrum: A case report","volume":"97","author":"Digby","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R41-8-20240829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/pde.13411","article-title":"Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis","volume":"35","author":"Sch\u00f8sler","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"R42-8-20240829","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4103\/idoj.IDOJ_253_19","article-title":"Clinical implications of antifungal drug susceptibility testing of dermatophytes","volume":"10","author":"Khurana","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"R43-8-20240829","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijdvl.IJDVL_519_16","article-title":"Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center","volume":"83","author":"Mahajan","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R44-8-20240829","first-page":"ii","article-title":"Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines","volume":"3","author":"Dabas","year":"2017","journal-title":"J Fungi (Basel"},{"key":"R45-8-20240829","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/ijp.IJP_578_17","article-title":"Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin-A prospective, randomized comparative study","volume":"51","author":"Bhatia","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"R46-8-20240829","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4103\/idoj.IDOJ_167_21","article-title":"Oral isotretinoin combined with oral terbinafine versus oral terbinafine alone to treat recurrent dermatophytosis: An open-label randomised clinical trial","volume":"12","author":"Verma","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"R47-8-20240829","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/ijdvl.IJDVL_526_17","article-title":"End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients","volume":"84","author":"Singh","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R48-8-20240829","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4103\/ijdvl.IJDVL_717_18","article-title":"'End of the road for terbinafine' in dermatophytosis: Is it a valid conclusion?","volume":"84","author":"Bhattacharjee","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R50-8-20240829","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/ijd.IJD_548_19","article-title":"Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation","volume":"65","author":"Singh","year":"2020","journal-title":"Indian J Dermatol"},{"key":"R51-8-20240829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bjd.19562","article-title":"The science and rationale of arriving at the correct drug and dosimetry of griseofulvin, fluconazole, terbinafine and itraconazole in superficial dermatophyte infections: An important step before a pragmatic trial","volume":"184","author":"Sardana","year":"2021","journal-title":"Br J Dermatol"},{"key":"R52-8-20240829","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1997.03890460029004","article-title":"Safety of oral terbinafine: Results of a postmarketing surveillance study in 25,884 patients","volume":"133","author":"Hall","year":"1997","journal-title":"Arch Dermatol"},{"key":"R53-8-20240829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1992.tb00013.x","article-title":"Special features of the clinical use of oral terbinafine in the treatment of fungal diseases","volume":"126","author":"Villars","year":"1992","journal-title":"Br. J. Dermatol"},{"key":"R54-8-20240829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1439-0507.2003.00953.x","article-title":"Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day-1) in the treatment of cutaneous or lymphocutaneous sporotrichosis","volume":"47","author":"Chapman","year":"2004","journal-title":"Mycoses"},{"key":"R55-8-20240829","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0009-9236(99)70065-2","article-title":"Investigation of terbinafine as a CYP2D6 inhibitor in vivo","volume":"65","author":"Abdel-Rahman","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R56-8-20240829","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4103\/idoj.IDOJ_233_20","article-title":"Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT)","volume":"11","author":"Rengasamy","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R58-8-20240829","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000074118","article-title":"Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy","volume":"207","author":"Gupta","year":"2003","journal-title":"Dermatol"},{"key":"R59-8-20240829","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/AAC.37.10.2101","article-title":"Effects of itraconazole on cytochrome P-450-dependent sterol 14a-demethylation and reduction of 3-ketosteroids in Cryptococcus neoforinans. Antimicrob","volume":"37","author":"Vanden","year":"1993","journal-title":"Agents Chemother"},{"key":"R60-8-20240829","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.40.2.279","article-title":"Antifungal agents: Chemotherapeutic targets and immunologic strategies. Antimicrob","volume":"40","author":"Georgopapadakou","year":"1996","journal-title":"Agents Chemother"},{"key":"R61-8-20240829","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1574-6968.1991.tb04517.x","article-title":"Biochemical changes associated with the antifungal action of the triazole ICI 153,066 on Candida albicans and Trichophyton quinckeanum","volume":"79","author":"Barrett-Bee","year":"1991","journal-title":"FEMS Microbiol Lett"},{"key":"R62-8-20240829","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1006\/abbi.1993.1100","article-title":"The structural requirements of sterols for membrane function in Saccharomyces cerevisiae","volume":"300","author":"Nes","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"R63-8-20240829","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.38.9.2029","article-title":"Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole","volume":"38","author":"Ghannoum","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-8-20240829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: An overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"R66-8-20240829","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/myc.13367","article-title":"Predicting a therapeutic cut-off serum level of itraconazole in recalcitrant tinea corporis and cruris\u2014A prospective trial","volume":"64","author":"Khurana","year":"2021","journal-title":"Mycoses"},{"key":"R67-8-20240829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/ijdvl.IJDVL_715_17","article-title":"Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis-time to look beyond the MIC data?","volume":"84","author":"Khurana","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R68-8-20240829","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/ijd.16622","article-title":"Treatment of recalcitrant cases of tinea corporis\/cruris caused by T. mentagrophytes-interdigitale complex with mutations in ERG11 ERG 3, ERG4, MDR1 MFS genes and SQLE and their potential implications","volume":"62","author":"Bhattacharyya","year":"2023","journal-title":"Int J Dermatol"},{"key":"R69-8-20240829","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ddr.430080136","article-title":"Itraconazole (R 51 211): A clinical review of its antimycotic activity in dermatology, gynecology, and internal medicine","volume":"8","author":"Cauwenbergh","year":"1986","journal-title":"Drug Dev Res"},{"key":"R70-8-20240829","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/clinids\/9.Supplement_1.S100","article-title":"Itraconazole in the treatment of superficial mycoses: An open trial of 40 cases","volume":"9","author":"Sa\u00fal","year":"1987","journal-title":"Rev Infect Dis"},{"key":"R71-8-20240829","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/clinids\/9.Supplement_1.S104","article-title":"Itraconazole in the treatment of dermatophytoses: A comparison of two daily dosages","volume":"9","author":"Degreef","year":"1987","journal-title":"Rev Infect Dis"},{"key":"R72-8-20240829","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0190-9622(90)70255-G","article-title":"Itraconazole in the management of chronic dermatophytosis","volume":"23","author":"Hay","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"R73-8-20240829","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1093\/clinids\/9.Supplement_1.S119","article-title":"Itraconazole in the treatment of tinea corporis: A pilot study","volume":"9","author":"Nuijten","year":"1987","journal-title":"Rev Infect Dis"},{"key":"R74-8-20240829","first-page":"118","article-title":"Management of fungal skin infections with 15 days itraconazole treatment: A worldwide review","volume":"71","author":"De Doncker","year":"1990","journal-title":"Br J Clin Pract Suppl"},{"key":"R75-8-20240829","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000246883","article-title":"Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and\/or tinea cruris","volume":"189","author":"Parent","year":"1994","journal-title":"Dermatology"},{"key":"R76-8-20240829","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1439-0507.1998.tb00714.x","article-title":"Itraconazole in the treatment of tinea corporis and tinea cruris: Comparison of two treatment schedules","volume":"41","author":"Boonk","year":"1998","journal-title":"Mycoses"},{"key":"R77-8-20240829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12895-018-0073-1","article-title":"Expert consensus on the management of dermatophytosis in India (ECTODERM India)","volume":"18","author":"Rajagopalan","year":"2018","journal-title":"BMC Dermatol"},{"key":"R78-8-20240829","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17512433.2019.1604218","article-title":"Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses","volume":"12","author":"Sardana","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R79-8-20240829","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/idoj.IDOJ_339_17","article-title":"A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario","volume":"9","author":"Sardana","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R80-8-20240829","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/09546634.2019.1708848","article-title":"An exploratory pilot analysis of the optimal pellet number in 100 mg of itraconazole capsule to maximize the surface area to satisfy the Noyes-Whitney equation","volume":"32","author":"Sardana","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"R81-8-20240829","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/myc.13551","article-title":"Correlation of plasma levels of itraconazole with treatment response at 4weeks in chronic dermatophytosis: Results of a randomised controlled trial","volume":"66","author":"Bhalavi","year":"2023","journal-title":"Mycoses"},{"key":"R82-8-20240829","first-page":"211","article-title":"Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum","volume":"75","author":"Pierard-Franchimont","year":"1995","journal-title":"Ann Soc Belg Med Trop"},{"key":"R83-8-20240829","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2006.11.027","article-title":"Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance","volume":"30","author":"Pasqualotto","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R84-8-20240829","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jamadermatol.2022.3745","article-title":"Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea Corporis\/Cruris: A randomized clinical trial","volume":"158","author":"Khurana","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R85-8-20240829","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/IDR.S170706","article-title":"Trough concentration of itraconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R86-8-20240829","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R87-8-20240829","doi-asserted-by":"crossref","first-page":"e0281514","DOI":"10.1371\/journal.pone.0281514","article-title":"No evidence of resistance to itraconazole in a prospective real-world trial of dermatomycosis in India","volume":"18","author":"Handa","year":"2023","journal-title":"PLoS One"},{"key":"R88-8-20240829","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"R89-8-20240829","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7573\/dic.2022-8-1","article-title":"Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis","volume":"12","author":"Dhoot","year":"2023","journal-title":"Drugs Context"},{"key":"R90-8-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_618_20","article-title":"Super bioavailable itraconazole and its place and relevance in recalcitrant dermatophytosis: Revisiting skin levels of itraconazole and minimum inhibitory concentration data","volume":"12","author":"Sardana","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"R91-8-20240829","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R92-8-20240829","doi-asserted-by":"crossref","first-page":"101306","DOI":"10.1016\/j.mycmed.2022.101306","article-title":"Multidrug resistant tinea corporis\/cruris: Response to voriconazole","volume":"32","author":"Khurana","year":"2022","journal-title":"J Mycol Med"},{"key":"R93-8-20240829","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/ijd.15226","article-title":"Multidrug-resistant Trichophyton mentagrophytes genotype VIII in an Iranian family with generalized dermatophytosis: Report of four cases and review of literature","volume":"60","author":"Fattahi","year":"2021","journal-title":"Int J Dermatol"},{"key":"R94-8-20240829","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00105-019-4431-7","article-title":"Extensive tinea corporis due to a terbinafine-resistant Trichophyton mentagrophytes isolate of the Indian genotype in a young infant from Bahrai n in Germany]","volume":"70","author":"S\u00fc\u00df","year":"2019","journal-title":"Hautarzt"},{"key":"R95-8-20240829","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/ced.14824","article-title":"Is there a rationale for the use of voriconazole in dermatophytosis in the absence of mycological and mutational data? An urgent need for antifungal stewardship","volume":"46","author":"Sardana","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"R96-8-20240829","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ced.14799","article-title":"Evaluation of efficacy and safety of oral voriconazole in the management of recalcitrant and recurrent dermatophytosis","volume":"47","author":"Chandrashekar","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"R97-8-20240829","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/myc.13517","article-title":"Voriconazole is superior to combined itraconazole\/isotretinoin therapy and itraconazole monotherapy in recalcitrant dermatophytosis","volume":"65","author":"Khattab","year":"2022","journal-title":"Mycoses"},{"key":"R98-8-20240829","first-page":"17","article-title":"Efficacy of voriconazole among 500 dermatophytes patients: A study in a Tertiary Care Hospital, Cumilla, Bangladesh","volume":"9","author":"Hoq","year":"2020","journal-title":"Am J Dermatol Venereol"},{"key":"R99-8-20240829","doi-asserted-by":"crossref","first-page":"330","DOI":"10.53350\/pjmhs22162330","article-title":"Efficacy of oral voriconazole in the treatment of dermatophyte infections (Tinea Corporis and Cruris)","volume":"16","author":"Shahzad","year":"2022","journal-title":"Pakistan J Medical Health Sc"},{"key":"R100-8-20240829","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety \u2212 A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R101-8-20240829","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R102-8-20240829","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/clinids\/14.Supplement_1.S77","article-title":"Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis","volume":"14","author":"Montero-Gei","year":"1992","journal-title":"Clin Infect Dis"},{"key":"R103-8-20240829","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00044011-199612020-00001","article-title":"Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidosis: A multicentre, open, noncomparative study","volume":"12","author":"Kotogyan","year":"1996","journal-title":"Clin Drug Investig"},{"key":"R104-8-20240829","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijdvl.IJDVL_1012_16","article-title":"Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics","volume":"83","author":"Sardana","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R105-8-20240829","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1439-0507.2008.01505.x","article-title":"Widespread, chronic, and fluconazole-resistant Trichophyton rubrum infection in an immunocompetent patient","volume":"51","author":"Balci","year":"2008","journal-title":"Mycoses"},{"key":"R106-8-20240829","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2230.1993.tb00987.x","article-title":"Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat","volume":"18","author":"Faergemann","year":"1993","journal-title":"Clin Exp Dermatol"},{"key":"R107-8-20240829","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0190-9622(82)70015-5","article-title":"Ketoconazole in griseofulvin-resistant dermatophytosis","volume":"6","author":"Robertson","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"R108-8-20240829","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0190-9622(82)70037-4","article-title":"Oral ketoconazole for dermatophyte infections","volume":"6","author":"Cox","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"R109-8-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198223010-00001","article-title":"Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections","volume":"23","author":"Heel","year":"1982","journal-title":"Drugs"},{"key":"R110-8-20240829","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475415574970","article-title":"The rise and fall of oral ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"R111-8-20240829","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4269\/ajtmh.21-0505","article-title":"Real World Analysis of Response Rate and Efficacy of Oral Ketoconazole in Patients with Recalcitrant Tinea Corporis and Cruris","volume":"106","author":"Arora","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"R112-8-20240829","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1128\/JCM.42.7.2977-2979.2004","article-title":"Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes","volume":"42","author":"Ghannoum","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R113-8-20240829","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1468-3083.2006.01396.x","article-title":"What defines the quality of patient care in tinea pedis?","volume":"20","author":"Mistik","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R114-8-20240829","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/ijd.12100","article-title":"In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey","volume":"52","author":"Yeni\u015fehirli","year":"2013","journal-title":"Int J Dermatol"},{"key":"R115-8-20240829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archderm.1981.01650010022016","article-title":"Griseofulvin-resistant dermatophytosis correlates with in vitro resistance","volume":"117","author":"Artis","year":"1981","journal-title":"Arch Dermatol"},{"key":"R116-8-20240829","first-page":"103","article-title":"Griseofulvin: Biology and clinical usefulness. A review","volume":"23","author":"Anderson","year":"1965","journal-title":"Ann Allergy"},{"key":"R117-8-20240829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000247498","article-title":"Itraconazole compared with griseofulvin in the treatment of tinea corporis\/cruris and tinea pedis\/manus: An interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile","volume":"184","author":"Lachapelle","year":"1992","journal-title":"Dermatology"},{"key":"R118-8-20240829","doi-asserted-by":"crossref","first-page":"e0032121","DOI":"10.1128\/AAC.00321-21","article-title":"Checkerboard analysis to evaluate synergistic combinations of existing antifungal drugs and propylene glycol monocaprylate in isolates from recalcitrant tinea corporis and cruris patients harboring squalene epoxidase gene mutation","volume":"65","author":"Sardana","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R119-8-20240829","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/ijd.16362","article-title":"The emergence of Trichophyton indotineae: Implications for clinical practice","volume":"62","author":"Gupta","year":"2023","journal-title":"Int J Dermatol"},{"key":"R120-8-20240829","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09546634.2019.1675853","article-title":"Antifungal combination therapy in dermatophytosis: A clinical insight","volume":"31","author":"Sharma","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R121-8-20240829","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jac\/dkh434","article-title":"Combinations of antifungal agents in therapy-what value are they?","volume":"54","author":"Cuenca-Estrella","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R123-8-20240829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","article-title":"A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement","volume":"157","author":"Baran","year":"2007","journal-title":"Br J Dermatol"},{"key":"R124-8-20240829","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/09546634.2019.1612835","article-title":"Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis","volume":"31","author":"Sharma","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R125-8-20240829","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.183632","article-title":"Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole","volume":"82","author":"Ardeshna","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R126-8-20240829","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0378-6323.194292","article-title":"Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis?","volume":"83","author":"Srivastava","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R127-8-20240829","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/pai.12181","article-title":"Systemic treatment with isotretinoin suppresses itraconazole blood level in chronic granulomatous disease","volume":"25","author":"von Bernuth","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"R128-8-20240829","doi-asserted-by":"crossref","first-page":"e01627","DOI":"10.1128\/AAC.01627-18","article-title":"In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R129-8-20240829","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/jam.14126","article-title":"Antifungal activity of immunosuppressants used alone or in combination with fluconazole","volume":"126","author":"Zhang","year":"2019","journal-title":"J Appl Microbiol"},{"key":"R130-8-20240829","first-page":"140","article-title":"Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations","volume":"52","author":"Nyilasi","year":"2014","journal-title":"Med Mycol"},{"key":"R131-8-20240829","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0190-9622(94)70153-9","article-title":"Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris","volume":"31","author":"Pariser","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"R132-8-20240829","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/ijdvl.IJDVL_807_17","article-title":"Risk factors for chronic and chronic-relapsing tinea corporis, tinea cruris and tinea faciei: Results of a case-control study","volume":"85","author":"Singh","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_832_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:09:19Z","timestamp":1787771359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_832_23"}},"subtitle":["Separating Evidence from Hype\u2014A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_832_23","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}